Lumos Pharma, Inc.

NASDAQ:LUMO

3.92 (USD) • At close September 19, 2024
Bedrijfsnaam Lumos Pharma, Inc.
Symbool LUMO
Munteenheid USD
Prijs 3.92
Beurswaarde 31,846,237
Dividendpercentage 0%
52-weken bereik 1.37 - 4.55
Industrie Biotechnology
Sector Healthcare
CEO Mr. Richard J. Hawkins
Website https://www.lumos-pharma.com

An error occurred while fetching data.

Over Lumos Pharma, Inc.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.

Vergelijkbare Aandelen

Movano Inc. logo

Movano Inc.

MOVE

0.36 USD

Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

VRCA

1.94 USD

Cyteir Therapeutics, Inc. logo

Cyteir Therapeutics, Inc.

CYT

3.02 USD

Curis, Inc. logo

Curis, Inc.

CRIS

5.93 USD

LifeMD, Inc. logo

LifeMD, Inc.

LFMD

5.28 USD

Mustang Bio, Inc. logo

Mustang Bio, Inc.

MBIO

0.223 USD

ImmuCell Corporation logo

ImmuCell Corporation

ICCC

3.63 USD

Neuronetics, Inc. logo

Neuronetics, Inc.

STIM

0.947 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)